ACCC Launches New Public Policy Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ROCKVILLE, Maryland-The Association of Community Cancer Centers (ACCC) has launched a new website (www.accc-cancer.org/publicpolicy) dedicated to regulatory and legislative issues affecting patients with cancer. The website will assist in the education of patients and their families about public policy that affects cancer care.

ROCKVILLE, Maryland—The Association of Community Cancer Centers (ACCC) has launched a new website (www.accc-cancer.org/publicpolicy) dedicated to regulatory and legislative issues affecting patients with cancer. The website will assist in the education of patients and their families about public policy that affects cancer care.

The new website also was designed to serve as a tool to bring patients and physicians together to discuss important cancer issues, such as new therapeutic modalities, insurance reimbursement, and clinical trials. The public policy site features information for patients and their families regarding access to cancer care, and details on oral cancer drugs and the congressional actions affecting use of such drugs.

The site features a section on legislative alerts, general information about Capitol Hill legislators, and tips for patients with cancer and their families on communicating with their representatives. The site also provides a directory of ACCC member hospitals and physicians, a list of patient advocacy organizations, and contact information for representatives and senators.

"By providing patients and families with information about the public policies that impact cancer care and helping them learn about the legislative process, they will be able to fully act on their rights and enlist the government in their personal battles against cancer," said Margaret A. Riley, MN, RN, of ACCC’s Ad Hoc Committee for Advocacy. 

Recent Videos
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
Related Content